Compare HOVR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | UNCY |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.3M | 100.6M |
| IPO Year | 2022 | 2021 |
| Metric | HOVR | UNCY |
|---|---|---|
| Price | $1.27 | $3.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.33 | ★ $28.40 |
| AVG Volume (30 Days) | 521.6K | ★ 1.0M |
| Earning Date | 10-09-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10,044.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $3.33 |
| 52 Week High | $3.68 | $8.74 |
| Indicator | HOVR | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 42.19 |
| Support Level | $1.25 | $3.34 |
| Resistance Level | $2.07 | $4.18 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 54.84 | 40.00 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.